General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Share buy-back

Novartis started its first share buy-backs in 1999. Since then, shares valued at approx. CHF 19 billion in total have been repurchased.

At the annual general meeting of shareholders of Novartis in February 2008, the shareholders of Novartis granted the current authorization to the Novartis Board to repurchase Novartis shares up to a maximum amount of CHF 10 billion via a second trading line on the SIX Swiss Exchange.

Stock chart
Q3 Results 2013

On Thursday, April 24, Novartis will announce its results for the first quarter of 2014